Novartis stock at CHF 121.22 on September 28, 2026
Published on 09/28/2026 at 22:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis shares traded at CHF 121.22 on the SIX Swiss Exchange at 9:28 a.m. on September 28, 2026, up 1.20 percent from the session's opening level, according to finanzen.ch. The stock opened at CHF 120.78 and reached CHF 121.24 during the session at the time of the report.
Recent regulatory development
In a September 18, 2026 release, Novartis said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Cosentyx, or secukinumab, in polymyalgia rheumatica. The recommendation covers adults who have had an inadequate response to steroids or who relapse during steroid tapering.
Novartis said the opinion was supported by the Phase III REPLENISH trial. The company reported that the trial met its primary and secondary endpoints across the 300-milligram and 150-milligram Cosentyx treatment arms, including complete sustained remission and time to additional treatment through week 52.
Clinical-trial update
In a separate September 8, 2026 announcement, Novartis said its Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 did not demonstrate a statistically significant improvement versus placebo on the primary endpoint of video hand opening time. The company said evidence of clinical activity was observed in secondary endpoints and exploratory analyses, and that it was evaluating the full dataset.
